moomoo ai

Summary by Moomoo AI
iBio Inc, a preclinical stage biotechnology company, has filed a prospectus related to the resale of up to 10,574,556 shares of common stock by identified selling stockholders. These shares include 2,701,315 outstanding shares held by the selling stockholders, 2,585,963 shares issuable upon the exercise of pre-funded warrants, and 5,287,278 shares issuable upon the exercise of outstanding warrants. The selling stockholders acquired these shares and warrants through a private placement transaction that closed on April 1, 2024. iBio Inc will not offer any shares under this prospectus and will not receive any proceeds from the sale of the shares by the selling stockholders. However, the company will receive proceeds from the cash exercise of the pre-funded warrants and the series E common warrants. The selling stockholders may sell their shares through public or private transactions at prevailing market prices or at negotiated prices. The registration of these shares does not necessarily mean that the selling stockholders will sell any or all of their shares, but it fulfills iBio Inc's contractual obligations to allow for the resale of these shares. The company's common stock is listed on the NYSE American LLC under the symbol 'IBIO.' As of April 23, 2024, the last reported sale price of iBio Inc's common stock was $1.90 per share. The date of the prospectus is April 24, 2024.